Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Ganna Blazhenets, David N Soleimani-Meigooni, Isabel Elaine Allen, Gil D Rabinovici, Renaud La Joie, Meta-Centiloid Study Group, Breton Michael Asken, Alexandre Bejanin, Tammie L.S. Benzinger, Tobey J. Betthauser, Marina Blūma, Stéphanie Bombois, Pierrick Bourgeat, Vincent Bouteloup, Meredith N. Braskie, Natalie Bryant, Santiago Bullich, María C. Carrillo, Kaitlin Blackstone Casaletto, Dave M. Cash, Chiung‐Chih Chang, Hsin‐I Chang, Yishu Chao, Geneviève Chêne, Gaël Chetelat, William Coath, Lyduine Eisa Collij, Lise Colmant, María M. Corrada, Bradford Clark Dickerson, Bruno Dubois, Alfonso Fajardo, Gill Farrar, Lars Frings, Giovanni Battista Frisoni, Valentina Garibotto, Johannes S. Gnörich, Brian Andrew Gordon, Yuna Gu, Yihui Guan, Bernard Jimmy Hanseeuw, Oskar Hansson, Theresa M. Harrison, ST Huang, Leonardo Iaccarino
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
The neuropathological diagnosis of Alzheimer’s disease.
10.1186/s13024-019-0333-5 · 2019
The role of amyloid PET in imaging neurodegenerative disorders: a review.
10.2967/jnumed.121.263195 · 2022
Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup.
10.1002/alz.13859 · 2024
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.
10.1016/j.nicl.2025.103765 · 2025
The role of amyloid-ß and tau PET in the new era of Alzheimer disease therapies.
10.2967/jnumed.124.268339 · 2025
Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
10.1002/alz.14338 · 2025
Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
10.1001/jama.2023.13239 · 2023
Lecanemab in early Alzheimer’s disease.
10.1056/nejmoa2212948 · 2023
TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer’s disease.
10.1002/alz.70293 · 2025
Lecanemab: appropriate use recommendations.
10.14283/jpad.2023.30 · 2023
Donanemab: appropriate use recommendations.
10.1016/j.tjpad.2025.100150 · 2025
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies.
10.1002/alz.70997 · 2025
The AHEAD 3-45 Study: design of a prevention trial for Alzheimer’s disease.
10.1002/alz.12748 · 2023
Donanemab in preclinical Alzheimer’s disease: screening and baseline data from TRAILBLAZER-ALZ 3.
10.1002/alz.70662 · 2025
Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD Diagnostic and Patient Management Study.
10.2967/jnumed.124.268119 · 2025
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.
10.1016/j.jalz.2014.07.003 · 2015
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology.
10.1016/j.jalz.2018.09.001 · 2019
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.
10.1002/alz.14336 · 2024
Statistical evaluation of a biomarker.
10.1097/aln.0b013e3181d47604 · 2010
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025.
10.2337/dc25-s002 · 2025
Patients with “gray zone” PSA levels: application of prostate MRI and MRS in the diagnosis of prostate cancer.
10.1002/jmri.28505 · 2023
2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
10.1161/cir.0000000000000678
Acceptable performance of blood biomarker tests of amyloid—recommendations from the Global CEO Initiative on Alzheimer’s Disease.
10.1038/s41582-024-00977-5 · 2024
Genetics of Alzheimer disease.
10.1177/0891988710383571 · 2010
Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition.
10.1016/j.jalz.2018.01.002 · 2018
Variant-dependent heterogeneity in amyloid ß burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study.
10.1016/s1474-4422(21)00375-6 · 2022
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease.
10.1093/braincomms/fcae159 · 2024
Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.
10.1017/s1041610297004870 · 1997
“Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician.
10.1016/0022-3956(75)90026-6 · 1975
Categorisation and minoritisation.
10.1136/bmjgh-2020-004508 · 2020
Updated guidance on the reporting of race and ethnicity in medical and science journals.
10.1001/jama.2021.13304 · 2021
Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease.
10.1212/wnl.0000000000000431 · 2014
Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation.
10.1212/wnl.0000000000011214 · 2021
Validation of amyloid PET positivity thresholds in Centiloid: a multisite PET study approach.
10.1186/s13195-021-00836-1 · 2021
Concordance between amyloid-PET quantification and real-world visual reads.
10.1001/jamaneurol.2025.2218 · 2025
Assessing a mixture model for clustering with the integrated completed likelihood.
10.1109/34.865189 · 2000
Index for rating diagnostic tests.
10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 · 1950
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
10.1001/jama.2015.4668 · 2015
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
10.1186/s13195-019-0478-z · 2019
Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study.
10.1212/wnl.0000000000200287 · 2022
No additional external references are available.